Dr Ashley Yocum speaks to ecancer about a study presented at ASH 2024 as part of the Beat AML master clinical trial.

The study examines MPM1 and KMT2A mutations in AML patients treated with menin inhibitors, revealing higher mutation rates in younger patients.

She reports that in patients aged 60 and older, results showed that 18.9% had MPM1 mutations and 3.6% KMT2A rearrangements.

Median overall survival rates vary significantly based on treatment type, with intensive chemotherapy yielding the best outcomes for the NPM1 cohort and a KMT2A targeted therapy the highest in the KMT2A cohort.

Dr Yocum hopes for FDA approval for KMT2A treatments in the newly-diagnosed setting.